Welcome to our dedicated page for Zai Lab SEC filings (Ticker: ZLAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Zai Lab Limited (ZLAB) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures related to its American Depositary Shares listed on the Nasdaq Global Market. Zai Lab is a research-based, commercial-stage biopharmaceutical company based in China and the United States, focused on oncology, immunology, neuroscience, and infectious disease. Its SEC filings offer detailed information on financial performance, risk factors, capital structure, and key corporate agreements.
Through this page, users can review Zai Lab’s current reports on Form 8-K, which have covered topics such as quarterly financial results and the entry into a material definitive agreement for a renminbi-denominated revolving credit facility to support working capital needs in mainland China. These filings also describe how certain information, including earnings press releases furnished as exhibits, is treated for purposes of the Securities Exchange Act of 1934.
In addition to 8-Ks, investors can use this page as a starting point to locate Zai Lab’s annual and other periodic reports filed with the SEC, which discuss its dual-engine strategy, commercial portfolio in China, and global research and development programs. For a biopharmaceutical company like Zai Lab, these documents are important for understanding product revenue sources, R&D investment, licensing arrangements for medicines such as VYVGART, NUZYRA, ZEJULA, AUGTYRO, and COBENFY, and the financial implications of its pipeline.
Stock Titan enhances the raw filing data with AI-powered summaries that highlight the main points of lengthy documents, helping readers quickly identify items such as new credit facilities, changes in operations, or significant clinical and commercial milestones referenced in the filings. Real-time updates from EDGAR, combined with organized access to forms including 8-K and other SEC documents, allow users to monitor ZLAB’s regulatory reporting and corporate actions efficiently.
ZLAB files a notice of proposed sale of 1,281 American Depositary Shares with an aggregate reported value of $23,862.72 dated 03/13/2026. The filing identifies the sale method as related to Restricted Stock Vesting and lists recent dispositions by Frazor T. Edmondson.
The record shows two dispositions in the prior three months: 8,651 ADS sold on 12/16/2025 for $148,278.14, and 15,569 ADS sold on 03/05/2026 for $296,745.14.
ZLAB reporting person Rafael Amado reported dispositions of American Depositary Shares. The filing lists sales of 10,787 ADS on 12/31/2025 for $188,033.59 and 10,000 ADS on 03/03/2026 for $173,800.00. The filing also shows 2,957 ADS vested as restricted stock on 03/12/2026 for compensation.
Zai Lab Ltd Chairperson and CEO exercised stock options and reported related ADS transactions. On March 10, 2026, the reporting person exercised options to acquire 261,092 American Depositary Shares (ADSs) at $1.74 per ADS and received an additional 2,655 ADSs upon vesting of restricted share units (RSUs). To cover taxes on RSU vesting, 116,936 ADSs were automatically sold at $19.41 per ADS. On March 11, 2026, 1,067 ADSs were sold at $19.084 per ADS under a Rule 10b5-1 trading plan adopted on November 11, 2025. Following these transactions, the reporting person directly held 1,109,905 ADSs, with 461,092 stock options and 7,965 RSUs remaining outstanding. Each ADS represents ten Ordinary Shares of Zai Lab.
ZLAB reported a Form 144 notice evidencing proposed sales of American Depositary Shares by Ying Du. The filing lists four dispositions of 50,000 ADS each on 03/04/2026, 03/05/2026, 03/06/2026 and 03/09/2026, with reported gross proceeds shown per trade.
Zai Lab Ltd chairperson and CEO Du Ying reported option exercises and share sales under a pre-arranged trading plan. On March 6 and March 9, 2026, Du Ying exercised stock options for a total of 100,000 American Depositary Shares at an exercise price of $1.74 per ADS and then sold 100,000 ADS in open-market transactions at weighted average prices of $19.4187 and $19.0293 per ADS. Following these transactions, Du Ying directly holds 964,161 ADS. The filing notes that each ADS represents ten ordinary shares and that all trades were executed pursuant to a Rule 10b5-1 trading plan adopted on November 11, 2025, indicating the sales were pre-scheduled rather than opportunistic.
ZLAB filed a Form 144 notice relating to sales of American Depositary Shares. The filing lists an intended sale of 50,000 ADS on 03/09/2026 through Fidelity Brokerage Services LLC and records executed sales by Ying Du of 50,000 ADS on 03/04/2026, 50,000 ADS on 03/05/2026, and 50,000 ADS on 03/06/2026 with reported dollar amounts of $958,155.00, $961,055.00, and $959,000.00 respectively.
Zai Lab Ltd Chief Legal Officer Edmondson Frazor Titus III reported an open-market sale of 15,569 American Depositary Shares at $19.06 per ADS on March 5, 2026, executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 12, 2025.
Following this transaction, he holds 3,517 ADS directly. Each ADS represents ten ordinary shares of Zai Lab, and the ADSs and ordinary shares are described as fully fungible.
Zai Lab Ltd chairperson and CEO Du Ying reported exercising stock options and selling shares in early March 2026. On March 4–5, 2026, Du Ying exercised options for a total of 100,000 American Depositary Shares (ADS), described as derivative exercises or conversions at $1.74 per ADS.
Over the same two days, Du Ying sold 100,000 ADS in open-market transactions at weighted average prices of $18.7769, $19.3176, and $19.2211 per ADS. After these trades, Du Ying directly owned 964,161 ADS. Each ADS represents ten ordinary shares, and all trades were executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 11, 2025.